NOW AVAILABLE: For the Vulvar and Vaginal Atrophy Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for 2016.

In the 2016 vulvar and vaginal atrophy market, Allergan’s Estrace Cream and Pfizer’s Premarin Cream consistently produced the largest proportion of the promotional volume received, distributing a shared total of nearly 70% of all new materials reviewed. A new competitor was poised to enter the market as TherapeuticsMD announced its NDA submission for Yuvvexy, which was accepted by the FDA with a PDUFA target action date of May 7th, 2017. Information on patient support and access was presented as a priority across brands, primarily to healthcare professionals, including Shionogi’s Osphena At Home, The Vine from Allergan, and savings programs from multiple products. Guidance on starting VVA conversations was provided, and efficacy was also highlighted, often touted alongside additional product benefits. Additional insights into marketing strategies and channel utilization are available with a subscription.

2016 VVA

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at

Ex-US Markets: Robin Cefalo at